Tuesday, March 5, 2024 Vaginal Ring and Oral Pre-Exposure Prophylaxis Found Safe for HIV Prevention Throughout Pregnancy Transmission electron micrograph of HIV-1 virus particles (pink) replicating from the plasma membrane of an H9 T cell. Image captured at the NIAID Integrated Research Facility in Fort Detrick, Maryland. Credit: NIAID Pregnant people are three times more likely to acquire HIV than those who are not pregnant. A NIAID-sponsored study presented at the 2024 Conference on Retroviruses and Opportunistic Infections showed that the dapivirine vaginal ring or oral PrEP was safe for HIV prevention throughout pregnancy. The large clinical study was conducted in South Africa, Uganda and Zimbabwe by the NIH-funded Microbicide Trials Network. National Institute of Allergy and Infectious Diseases  |  National Institutes of Health Update your subscriptions, modify your password or e-mail address, or stop subscriptions at any time on your Subscriber Preferences Page. You will need to use your e-mail address to log in. If you have questions or problems with the subscription service, please contact Subscriber Help. This service is provided to you at no charge by National Institute of Allergy and Infectious Diseases (NIAID).                             This email was sent to myhcistech.healthnews360@blogger.com using GovDelivery Communications Cloud on behalf of: National Institute of Allergy and Infectious Diseases · 5601 Fishers Lane · Bethesda, MD 20892 · 1-866-284-4107